Cytokines in immunogenic cell death: Applications for cancer immunotherapy

Cytokine

Volumn 97, Issue , 2017, Pages 123-132

  Showalter, Anne ^a   Limaye, Arati ^a   Oyer, Jeremiah L ^a   Igarashi, Robert ^a   Kittipatarin, Christina ^b   Copik, Alicja J ^a   Khaled, Annette R ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Cancer; Chemotherapeutics; Danger Associated Molecular Patterns (Damps); Immunotherapy; Stress response

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DAUNORUBICIN; DOXORUBICIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; INITIATION FACTOR 2ALPHA; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; MITOMYCIN; MITOXANTRONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PURINERGIC P2X7 RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; TUMOR NECROSIS FACTOR; ALARMIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MATURATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNOGENIC CELL DEATH; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ENDOPLASMIC RETICULUM STRESS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METASTASIS; MOUSE; NEOPLASM; PHYSIOLOGICAL STRESS; PROCEDURES;

ALARMINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CLINICAL TRIALS AS TOPIC; CYTOKINES; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASM METASTASIS; NEOPLASMS; STRESS, PHYSIOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85021068524     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2017.05.024     Document Type: Review

References (74)

1. Farkona, S., Diamandis, E.P., Blasutig, I.M., Cancer immunotherapy: the beginning of the end of cancer?. BMC Med., 14(1), 2016, 73.
2. Beatty, G.L., Gladney, W.L., Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 21:4 (2015), 687–692.
3. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348:6230 (2015), 69–74.
4. Razavi, S.-M., et al. Immune evasion strategies of glioblastoma. Front. Surg., 3, 2016, 11.
5. Preston, C.C., et al. Immunity and immune suppression in human ovarian cancer. Immunotherapy 3:4 (2011), 539–556.
6. Green, D.R., et al. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol., 9(5), 2009, 353.
7. Guo, C., et al. Therapeutic Cancer Vaccines: Past, Present and Future. Adv. Cancer Res. 119 (2013), 421–475.
8. Inoue, H., Tani, K., Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 21:1 (2014), 39–49.
9. Fucikova, J., et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Can. Res. 71:14 (2011), 4821–4833.
10. Michalak, M., et al. Calreticulin: one protein, one gene, many functions. Biochem. J. 344:Pt 2 (1999), 281–292.
11. Gold, L.I., et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 24:3 (2010), 665–683.
12. Yang, H., et al. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J. Leukoc. Biol. 93:6 (2013), 865–873.
13. Apetoh, L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med., 13, 2007.
14. Schlesinger, M.J., Heat shock proteins. J. Biol. Chem. 265:21 (1990), 12111–12114.
15. Schmitt, E., et al. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol. 81:1 (2007), 15–27.
16. Wang, R., et al. HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and PI3K pathways. J. Surg. Res. 136:1 (2006), 58–69.
17. Multhoff, P.D.G., Hyperthermia classic commentary: activation of natural killer (NK) cells by heat shock protein 70, Gabriele Multhoff, International Journal of Hyperthermia, 2002;18:576–585. Int. J. Hyperth. 25:3 (2009), 176–179.
18. Ghiringhelli, F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1[beta]-dependent adaptive immunity against tumors. Nat. Med. 15:10 (2009), 1170–1178.
19. Park, S.-H., et al. Activating transcription factor 3-mediated chemo-intervention with cancer chemokines in a noncanonical pathway under endoplasmic reticulum stress. J. Biol. Chem. 289:39 (2014), 27118–27133.
20. Zhang, P., et al. The GCN2 eIF2α Kinase Is Required for Adaptation to Amino Acid Deprivation in Mice. Mol. Cell. Biol. 22:19 (2002), 6681–6688.
21. Chakrabarti, A., Chen, A.W., Varner, J.D., A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 108:12 (2011), 2777–2793.
22. Yoshida, H., et al. XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor. Cell 107:7 (2001), 881–891.
23. Murphy, K., et al. Janeway's immunobiology. 2012, Garland Science, New York.
24. Wan, S., et al. Chemotherapeutics and radiation stimulate MHC Class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS ONE, 7(3), 2012, e32542.
25. Schafer, Z.T., Brugge, J.S., IL-6 involvement in epithelial cancers. J. Clin. Invest. 117:12 (2007), 3660–3663.
26. Waugh, D.J.J., Wilson, C., The Interleukin-8 pathway in cancer. Am. Assoc. Cancer Res. 14:21 (2008), 6735–6741.
27. Ross, M.E., Caligiuri, M.A., Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89:3 (1997), 910–918.
28. Inoue, S., Setoyama, Y., Odaka, A., Doxorubicin treatment induces tumor cell death followed by immunomodulation in a murine neuroblastoma model. Exp. Therap. Med. 7:3 (2014), 703–708.
29. Tesniere, A., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:4 (2009), 482–491.
30. Horton, T.M., et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 58:1 (2006), 13–23.
31. Gumulec, J., et al. Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages. Int. J. Mol. Sci., 15(12), 2014, 22960.
32. Manandhar, S., Lee, S., Kwak, M.-K., Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells. Arch. Pharmacal. Res. 33:5 (2010), 717–726.
33. Poljaková, J., et al. The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells. Interdiscip. Toxicol. 1:2 (2008), 186–189.
34. Tsai, C.-Y., et al. Synthesis and evaluation of aminothiazole-paeonol derivatives as potential anticancer agents. Molecules, 21(2), 2016, 145.
35. Zhao, X., et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials 102 (2016), 187–197.
36. Kawano, M., et al. Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol. Lett. 11:3 (2016), 2169–2175.
37. Schiavoni, G., et al. Cyclophosphamide synergizes with Type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Can. Res. 71:3 (2011), 768–778.
38. Menger, L., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med., 4(143), 2012, 143ra99.
39. Kepp, O., et al. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 1:9 (2012), 1640–1642.
40. Dudek-Perić, A.M., et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Can. Res. 75:8 (2015), 1603–1614.
41. Song, K.-H., et al. Induction of immunogenic cell death by radiation-upregulated karyopherin alpha 2 in vitro. Eur. J. Cell Biol. 95:6–7 (2016), 219–227.
42. Hsu, F.-T., et al. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice. Oncotarget 6:42 (2015), 44134–44150.
43. Tongu, M., et al. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol. Immunother. 59:5 (2010), 769–777.
44. Garg, A.D., et al. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 9:9 (2013), 1292–1307.
45. Garg, A.D., et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31:5 (2012), 1062–1079.
46. Dewaele, M., et al. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J. Cell Mol. Med. 15:6 (2011), 1402–1414.
47. Michaud, M., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334:6062 (2011), 1573–1577.
48. Panzarini, E., et al. In vitro and in vivo clearance of Rose Bengal Acetate-PhotoDynamic Therapy-induced autophagic and apoptotic cells. Exp. Biol. Med. 238:7 (2013), 765–778.
49. Fucikova, J., et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int. J. Cancer 135:5 (2014), 1165–1177.
50. Donnelly, O.G., et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 20:1 (2013), 7–15.
51. Angelova, A.L., et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J. Virol. 88:10 (2014), 5263–5276.
52. Duewell, P., et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ. 21:12 (2014), 1825–1837.
53. M. Lee, Phase I/II Clinical Study of Idarubicin Dose Intensification for Remission Induction Therapy in Acute Myeloid Leukemia Patients Age of 65 Years or Less. [Web Page] 2012 9-1-16 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT01518556?term=idarubicin&rank=2>.
54. M.D.A.C. Center, A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia, 2016 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02652871?term=idarubicin&rank=1>.
55. M. Clinic, Phase I Trial of Intraperitoneal Administration of (a) a CEA-Expressing Derivative, and (b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer, 2006 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT00408590?term=measles+virus&rank=4>.
56. U.o. Arkansas, A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma, 2014 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02192775?term=measles+virus&rank=3>.
57. University of California, D, A Diagnostic Feasibility Trial of a [14C]Oxaliplatin Microdosing Assay for Prediction of Chemoresistance to Oxaliplatin Chemotherapy, 2014 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02077998?term=oxaliplatin&rank=8>.
58. A.P.-H.d. Paris, Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients, 2016 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02906800?term=immunogenic+cell+death&rank=6>.
59. Soligenix, A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma, 2015 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02448381?term=hypericin&rank=2>.
60. O.G.C. KG, Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme, 2011 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT01301430?term=h-1pv&rank=1>.
61. O.G.C. KG, A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer. 2015 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02653313?term=h-1pv&rank=2>.
62. N. Bhardwaj, Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma, 2012 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT01740401?term=cyclophosphamide&rank=12>.
63. Siew, Y.-Y., et al. Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. Int. Immunol. 27:12 (2015), 621–632.
64. Fucikova, J., et al. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood 128:26 (2016), 3113–3124.
65. Duffy, A., et al. Autophagy modulation: a target for cancer treatment development. Cancer Chemother. Pharmacol. 75:3 (2015), 439–447.
66. Loi, S., et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. USA 110:27 (2013), 11091–11096.
67. C. Pfirschke et al., Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44(2): pp. 343–354.
68. J. Rios-Doria et al., Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia (New York, N.Y.), 2015. 17(8): pp. 661–670.
69. Abiko, K., et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112:9 (2015), 1501–1509.
70. Mandai, M., et al. Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22:10 (2016), 2329–2334.
71. Loke, P.N., Allison, J.P., PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100:9 (2003), 5336–5341.
72. U.H. Ghent, Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients, 2015 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT02441270?term=immunogenic+cell+death&rank=4>.
73. J.R. Kroep, Chemo-Immunotherapy: Observational Trial of Carboplatin-pegylated Liposomal Doxorubicin (PLD) or Doxorubicin Combination Chemotherapy With Tocilizumab, a Humanized Monoclonal Antibody Against the Human Interleukin-6 (IL-6) Receptor, and Pegylated Interferon Alpha (Peg-Intron) for Patients With Recurrent Ovarian Cancer, 2012 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT01637532?term=immunogenic+cell+death&rank=3>.
74. D.-H.M.Center, A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes, 2008 (cited 2017 1-26). < https://clinicaltrials.gov/ct2/show/NCT00789256?term=melphalan&rank=9>.